Text Search: Search by:

Refine your search with filters

Year:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

DOP077: Immunochip analysis identifies multiple susceptibility loci for collagenous colitisECCO '16 Amsterdam

Year: 2016

Authors:

G. Roda*¹, H. Jianzhong², Z. Zhongyang³, J. Torres¹, A. Chen⁴, R. Petras⁵, D. Pardi⁶, A. Juga⁷, G. Levi³, W. Cao⁸, F. Rieder⁹, I. Gordon¹⁰, K. Hao³, N. Harpaz¹¹, J. Cho¹², J.-F. Colombel¹², I. Peter³

¹Icahn School of Medicine, Gastroenterology, New York, New York, United States, ²Icahn School of Medicine, New York, New York, United States, ³Icahn School of Medicine at Mount Sinai, Medicine, New York, New York, United States, ⁴Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, New York, United States, ⁵Ameripath, Pathology, Cleveland, Ohio, United States, ⁶Mayo Clinic, Gastroenterology, Rochester, Minnesota, United States, ⁷New York-Presbyterian, Pathology, New York, New York, United States, ⁸University of Rochester, Pathology, Rochester, Minnesota, United States, ⁹University of Cleveland, Gastroenterology, Cleveland, Ohio, United States, ¹⁰Cleveland Clinic, Department of Anatomic Pathology, Cleveland, Ohio, United States, ¹¹Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, New York, United States, ¹²Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States

DOP078: Risk of malignancy in paediatric inflammatory bowel disease: results from the DEVELOP registryECCO '16 Amsterdam

Year: 2016

Authors:

M. Dubinsky¹, J. Hyams², R. Baldassano³, R. Colletti⁴, S. Cucchiara⁵, J. Escher⁶, W. Faubion⁷, J. Fell⁸, B. Gold⁹, A. Griffiths¹⁰, S. Koletzko¹¹, S. Kugathasan¹², J. Markowitz¹³, F. Ruemmele¹⁴, G. Veerman*¹⁵, H. Winter¹⁶, N. Masel¹⁷, K. Tang¹⁸, M. Thayu¹⁸

¹Mount Sinai, Icahn School of Medicine, New York, New York, United States, ²Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, ³The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, ⁴University of Vermont Children’s Hospital, Burlington, Vermont, United States, ⁵Sapienza University of Rome/University Hospital, Rome, Italy, ⁶Erasmus Mc-Sophia Children’s Hospital, Rotterdam, Netherlands, ⁷Mayo Clinic, Rochester, Minnesota, United States, ⁸Chelsea and Westminster Hospital, London, United Kingdom, ⁹Children’s Centre for Digestive Health Care, Atlanta, Georgia, United States, ¹⁰Hospital for Sick Children, University of Toronto, Department of Paediatrics, Toronto, Canada, ¹¹Ludwig Maximilians Universität München, Munich, Germany, ¹²Emory University, Atlanta, Georgia, United States, ¹³Cohen Children’s Medical Centre Of New York, New York, New York, United States, ¹⁴Hôpital Necker-Enfants Malades, Paris, France, ¹⁵Universitair Ziekenhaus, Brussels, Belgium, ¹⁶Mass General Hospital for Children, Boston, Massachusetts, United States, ¹⁷DOCS, Durham, North Carolina, United States, ¹⁸Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States

DOP079: Predictors of first neoplastic colonic lesion in patients with inflammatory bowel disease undergoing colonoscopic surveillanceECCO '16 Amsterdam

Year: 2016

Authors:

J. Kirchgesner*¹, M. Svrcek², C. Landman¹, A. Bourrier¹,  I. Nion-Larmurier¹, H. Sokol¹, J. Cosnes¹, J.-F. Flejou², L. Beaugerie¹

¹Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France, ²Saint-Antoine Hospital, AP-HP, Pathology, Paris, France

DOP080: Final results of a randomised study comparing high-definition colonoscopy alone with high- definition dye spraying and electronic virtual chromoendoscopy using iSCAN for detection of colonic neoplastic lesions during IBD surveillance colonoscopyECCO '16 Amsterdam

Year: 2016

Authors:

M. Iacucci*¹, M. Fort Gasia¹, A. Oluseyi¹, R. Panaccione¹, S. Gui X², S. Urbanski³, P. Minoo³, S. Ghosh¹

¹University of Calgary, Gastroenterology, Calgary, Canada, ²University of Calgary, Pathology, Calgary, Canada, ³University of Calgary, Calgary, Canada

DOP081: Outcomes of colitis-associated dysplasia after referral from the community to a tertiary centreECCO '16 Amsterdam

Year: 2016

Authors:

D. Rubin*, N. Krugliak Cleveland, D. Rodriquez

University of Chicago Medicine, Inflammatory Bowel Disease Centre, Chicago, Illinois, United States

DOP082: Proximity extension assay immunoassay technology identifies novel serum biomarkers that can diagnose and classify inflammatory bowel diseases: IBD Character ConsortiumECCO '16 Amsterdam

Year: 2016

Authors:

R. Kalla*¹, A. Ocklind², C. Petrén², N. Nordberg², N. Kennedy¹, N. Ventham¹, E. Pettersson², D. Bergemalm³, J. Lindström⁴, S. Vatn⁴, H. Hjortswang⁵, E. Nimmo¹, H. Drummond¹, P. Ricanek⁶, F. Dahl⁴, D. Wilson¹, J. Jahnsen⁴, F. Gomollón⁷, M. Pierik⁸, J. Söderholm⁹, M. Vatn⁴, J. Halfvarson³, IBD Character Consortium¹, J. Satsangi¹

¹University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, ²Olink, Bioscience, Uppsala, Sweden, ³Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, ⁴Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, ⁵Linköping University Hospital, Department of Gastroenterology, Linköping, Sweden, ⁶Akershus University Hospital, Deaprtment of Gastroenterology, Lorenskog, Norway, ⁷University of Zaragosa, Gastroenterology, Zaragosa, Spain, ⁸Maastricht University Medical Centre (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ⁹Linköping University Hospital, Department of Surgery, Linköping, Sweden

DOP083: Faecal calprotectin improves the predictive power of 3 practical indices for mucosal healing amongst patients with Crohn’s disease: results from PREDICTECCO '16 Amsterdam

Year: 2016

Authors:

W. Sandborn*¹, R. Panaccione², J.-F. Colombel³, E. Louis⁴, A. Robinson⁵, K. Wallace⁵, M. Bereswill⁶, M. Shapiro⁵, N. Chen⁵, M. Skup⁵, S. Wang⁵, R. Thakkar⁵, J. Chao⁵

¹University of California, San Diego, La Jolla, California, United States, ²University of Calgary, Medicine, Calgary, Canada, ³Centre Hospitalier Universitaire de Lille, Lille, France, ⁴University of Liège, Liège, Belgium, ⁵AbbVie Inc., North Chicago, Illinois, United States, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

DOP084: Identification of a potential new prognostic biomarker to select inflammatory bowel disease patients that fail standard therapyECCO '16 Amsterdam

Year: 2016

Authors:

M. S. Pereira¹, S. Campos¹, A. M. Dias¹, I. Pedroto², C. A. Reis^{1, 3}, L. Maia², R. Marcos-Pinto^{2, 3}, P. Lago², S. S. Pinho*^{1, 3}

¹Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & Institute for Research and Innovation in Health (i3S), Porto, Portugal, ²Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal, ³Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal

DOP085: Ileocolonic involvement and diagnosis is related to fragments of the extracellular matrix measured in serum of patients with Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

J. H. Mortensen*¹, M. D. Jensen², J. Kjeldsen², A. Krag², M. Karsdal¹, A.-C. Bay-Jensen¹

¹Nordic Bioscience, Biomarkers & Research, Herlev, Denmark, ²Odense University Hospital, Department of Gastroenterology, Odense, Denmark

DOP086: Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseasesECCO '16 Amsterdam

Year: 2016

Authors:

A. Buisson*^{1, 2}, E. Vazeille^{1, 2}, R. Minet Quinard³, M. Goutte^{1, 2}, D. Bouvier³, F. Goutorbe¹, B. Pereira⁴, N. Barnich², G. Bommelaer^{1, 2}

¹University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, ²UMR 1071 Inserm/Université d’Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, ³University Hospital G. Montpied, Biochemistry laboratory, Clermont-Ferrand, France, ⁴GM – Clermont-Ferrand University and Medical Centre, Biostatistics Unit, Clermont-Ferrand, France

DOP087: MMP degraded type III collagen is a novel serological biomarker for penetrating (Montreal B3) Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

W. T. van Haaften*^{1, 2}, J. H. Mortensen³, M. A. Karsdal³, A.-C. Bay-Jensen³, G. Dijkstra², P. Olinga¹

¹University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands, ²University Medical Centre Groningen, Department of Gastro-enterology and Hepatology, Groningen, Netherlands, ³Nordic Bioscience, Biomarkers and Research, Herlev, Denmark

DOP088: Inflammatory biomarkers in serum discriminate Crohn’s disease and ulcerative colitis from healthy controlsECCO '16 Amsterdam

Year: 2016

Authors:

E. Andersson*¹, D. Bergemalm¹, R. Kruse¹, M. D’Amato², D. Repsilber¹, J. Halfvarson¹

¹Örebro University, Faculty of Medicine and Health, Örebro, Sweden, ²Karolinska Institutet, Department of Medicine, Solna, Sweden

DOP089: Microbiota profiles in treatment-naïve Norwegian IBD and non-IBD patients: part of the European Union IBD character consortiumECCO '16 Amsterdam

Year: 2016

Authors:

P. Ricanek*¹, S. Vatn¹, T. Lindahl², E. Ciemniejewska², J. Jahnsen¹, C. Casen², M. H. Vatn¹

¹Akershus University Hospital, Department of Gastroenterology, Lørenskog/Nordbyhagen, Norway, ²Genetic Analysis AS, Oslo, Norway

DOP090: The role of the microbiome in clinical response to golimumab in ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

C. Monast*, S. Telesco, K. Li, K. Hayden, C. Brodmerkel

Janssen R & D, LLC, Spring House, Pennsylvania, United States

OP001: A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulas in Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

J. Panés*¹, D. García-Olmo², G. Van Assche³, J. F. Colombel⁴, W. Reinisch⁵, D. C. Baumgart⁶, M. Nachury⁷, M. Ferrante³, L. Kazemi-Shirazi⁵, J. C. Grimaud⁸, F. de la Portilla⁹, E. Goldin¹⁰, A. Leselbaum¹¹, M. C. Diez¹¹, S. Danese¹²

¹Hospital Clinic Barcelona, Barcelona, Spain, ²Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, ³University Hospitals Leuven, KU Leuven, Leuven, Belgium, ⁴Icahn School of Medicine at Mount Sinai, New York, New York, United States, ⁵Medical University of Vienna, Vienna, Austria, ⁶Charité Medical School - Humboldt-University of Berlin, Berlin, Germany, ⁷CHU Lille, Lille, France, ⁸Hôpital Nord, Marseille, France, ⁹Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰Sharee Zedek MC, Jerusalem, Israel, ¹¹TiGenix, Madrid, Spain, ¹²Istituto Clinico Humanitas, Milano, Italy

OP002: Histopathological response and remission after dual topical application of the Toll-like receptor 9 agonist DIMS0150 in patients with moderate-to-severe ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

R. Atreya*¹, A. Öst², C. Admyre³, A. Karlsson³, T. Knittel³, J. Kowalski³, F. Scaldaferi⁴, M. Neurath¹, C. Hawkey⁵

¹University of Erlangen-Nuernberg, Department of Medicine 1, Erlangen, Germany, ²Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden, ³Index Pharmaceuticals, Stockholm, Sweden, ⁴Catholic University of Rome, Internal Medicine Department / Gastroenterology Division, Rome, Italy, ⁵Nottingham University Hospitals, Department of Gastroenterology, Nottingham, United Kingdom

OP003: Predicting short and medium-term efficacy of the biosimilar infliximab: trough levels/do anti-drug antibody’s or clinical/biochemical markers play a more important role?ECCO '16 Amsterdam

Year: 2016

Authors:

P. A. Golovics*¹, Z. Vegh¹, M. Rutka², K. Gecse¹, A. Balint², K. Farkas², J. Banai³, L. Bene⁴, B. Gasztonyi⁵, T. Kristof⁶, L. Lakatos⁷, P. Miheller⁸, K. Palatka⁹, A. Patai¹⁰, A. Salamon¹¹, T. Szamosi³, Z. Szepes¹², G.T. Toth¹³, A. Vincze¹⁴, E. Biro¹⁵, B. Lovasz¹, Z. Kurti¹, F. Nagy¹², T. Molnar², P. Lakatos¹

¹Semmelweis University, First Department of Medicine, Budapest, Hungary, ²University of Szeged, First Department of Medicine, Szeged, Hungary, ³Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, ⁴Peterfy Hospital, First Department of Medicine, Budapest, Hungary, ⁵Zala County Hospital, Second Department of Medicine, Zalaegerszeg, Hungary, ⁶B-A-Z County and University Teaching Hospital, Second Department of Medicine, Miskolc, Hungary, ⁷Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, ⁸Semmelweis University, Second Department of Medicine, Budapest, Hungary, ⁹University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹⁰Markusovszky Hospital, First Department of Medicine and Gastroenterology, Szombathely, Iceland, ¹¹Tolna County Teaching Hospital, First Department of Gastroenterology, Szekszard, Hungary, ¹²University of Szeged, First Department of Internal Medicine, Szeged, Hungary, ¹³Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ¹⁴University of Pécs, First Department of Medicine, Pécs, Hungary, ¹⁵Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary

OP004: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohn’s diseaseECCO '16 Amsterdam

Year: 2016

Authors:

A. Stojmirovic*, R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman

Janssen R & D, LLC, Spring House, Pennsylvania, United States

OP005: A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

T. Billiet*¹, I. Cleynen¹, M. Ferrante², G. Van Assche², A. Gils³, S. Vermeire²

¹Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in Gastrointestinal Disorders (TARGID), Leuven, Belgium, ²University Hospitals Leuven, Gastroenterology -  Translational Research Centre for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ³KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium

OP006: Autophagy regulates dendritic cell migration through Rac1: implications for thiopurine therapyECCO '16 Amsterdam

Year: 2016

Authors:

M. Wildenberg*¹, P. Koelink², K. Diederen², A. te Velde², V. Nuij³, M. Peppelenbosch³, M. Nobis⁴, O. Sansom⁴, C.J. van der Woude³, G. D’Haens¹, G. van den Brink¹

¹Academic Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, ²Academic Medical Centre, Tytgat Institute, Amsterdam, Netherlands, ³Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, ⁴Beatson Institute for Cancer Research, Glasgow, United Kingdom